Hydroxyzine from topical phospholipid liposomal formulations: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model

AAPS PharmSci

Volumn 5, Issue 4, 2003, Pages

  Elzainy, Abeer A W ^a   Gu, Xiaochen ^a   Simons, F Estelle R ^b   Simons, Keith J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antihistamine; Hydroxyzine; L phosphatidylcholine; Liposomes; Rabbit; Skin

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; DRUG METABOLITE; HISTAMINE H1 RECEPTOR; HYDROXYZINE; LIPOSOME; PHOSPHATIDYLCHOLINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IN VIVO STUDY; NONHUMAN; PHOSPHOLIPID VESICLE; RABBIT; RANDOMIZATION; SKIN TEST; URTICARIA; ANIMAL; CHEMISTRY; DISEASE MODEL; HYPERSENSITIVITY; METABOLISM;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HYDROXYZINE; HYPERSENSITIVITY; LIPOSOMES; PHOSPHOLIPIDS; RABBITS; RANDOM ALLOCATION;

EID: 0347300797     PISSN: 15221060     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps050428     Document Type: Article

References (35)

1. 1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83:481-488.
2. Reynolds JEF. Martindale the Extra Pharmacopoeia. 30th ed. London, UK: The Pharmaceutical Press; 1993.
3. El Maghraby GMM, Williams AC, Barry BW. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm. 2000;196:63-74.
4. Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm. 1984;20:139-154.
5. Niemiec SM, Latta JM, Ramachandran C, Weiner ND, Roessler BJ. Perifollicular transgenic expression of human Interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulations in-vivo. J Pharm Sci. 1997;86:701-708.
6. Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N. Topical delivery of growth hormone releasing peptide using liposomal systems: an in-vitro study using hairless mouse skin. Life Sci. 1995;57:1293-1297.
7. Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in-vitro diffusion studies. Antimicrob Agents Chemother. 1990;34:107-110.
8. Mezei M. Liposomes in the topical application of drugs: a review. In: Gregoriadis G, ed. Liposomes as Drug Carriers, Recent Trends and Progress. New York, NY: John Wiley and Sons; 1988.
9. Krowczynski L, Stozek T. Liposomes as drug-carriers in the transdermal therapy. Pharmazie. 1984;39:627-629.
10. Patel HM. Liposomes as a controlled-release system. Biochem Soc Trans. 1985;13:513-516.
11. Price CI, Horton JW, Baxter CR. Liposome delivery of aminoglycosides in burn wounds. Surg Gynecol Obstet. 1992;174:414-418.
12. Price CI, Horton JW, Baxter CR. Topical liposomal delivery of antibiotics in soft tissue infection. J Surg Res. 1990;49:174-178.
13. Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microencapsul. 1995;12:149-154.
14. El-Ridy MS, Khalil RM. Free versus liposome-encapsulated lignocaine hydrochloride topical applications. Pharmazie. 1999;54:682-684.
15. Martin GP. Phospholipids as skin penetration enhancers. In: Walters KA, Hadgraft J, eds. Pharmaceutical Skin Penetration Enhancement. New York, NY: Marcel Dekker; 1993:57-60.
16. Yarosh DB. Topical application of liposomes. J Photochem Photobiol B. 1990;6:445-449.
17. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015-1019.
18. Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190:63-71.
19. Elzainy AAW, Gu X, Simons FER, Simons KJ. Effect of different phospholipids on the stability of liposomal formulations containing hydroxyzine [abstract]. AAPS PharmSci. 2002;4:4. Abstract R6110.
20. Olfert ED, Cross BM, Mcwilliam AA. Guide to the Care and Use of Experimental Animals. Ottawa ON, Canada: Canadian Council on Animal Care; 1993.
21. 1-receptor antagonist hydroxyzine. J Allergy Clin Immunol. 1984;73:69-75.
22. Watson WTA, Simons KJ, Chen XY, Simons FER. Cetirizine: a pharmacokinetics and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:457-464.
23. 1-receptor antagonists. J Allergy Clin Immunol. 2001;107:526-530.
24. Balen GPV, Caron G, Ermondi G, Pagliara A, Grandi T, Bouchard G, Fruttero R, Carrupt P-A, Testa B. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res. 2001;18:694-701.
25. Patel HM, Moghimi SM. Liposomes and the skin permeability barrier. In: Gregoriadis G, Florence AT, Patel HM, eds. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993:142-146.
26. Mezei M. Liposomes and the skin. In: Gregoriadis G, Florence AT, Patel HM, eds. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993:125-135.
27. 1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777-783.
28. 1-antihistamines: example of cetirizine. Ann Allergy Asthma Immunol. 1999;83:489-491.
29. Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J Microencapsul. 1990;7:479-489.
30. Bashir SJ, Maibach HI. Cutaneous metabolism during in-vitro percutaneous absorption. In: Bronaugh RL, Kraeling MEK, Yourick J, Hood HL, eds. Topical Absorption of Dermatological Products. New York, NY: Marcel Dekker; 2002:77-81.
31. Wohlarb W, Lasch J. Penetration kinetics of liposomal hydrocortisone in human skin. Dermatologica. 1987;174:18-22.
32. Wohlarb W, Lasch J. The effect of liposomal incorporation of topically applied hydrocortisone on its serum concentration and urinary excretion. Dermatol Monatsschr. 1989;175:348-352.
33. Mezei M, Gulasekharam V. Liposomes: a selective drug delivery system for the topical route of administration. 1. Lotion dosage form. Life Sci. 1980;26:1473-1477.
34. Harsanyi BB, Hilchie JC, Mezei M. Liposomes as drug carriers for oral ulcers. J Dent Res. 1986;65:1133-1141.
35. Foong WC, Harsany BB, Mezei M. Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms. In: Hanin I, Pepeu G, eds. Phospholipids. New York, NY: Plenum Press; 1990:279-282.